Antibody-mediated Rejection Clinical Trials

7 recruitingLast updated: July 25, 2026

There are 7 actively recruiting antibody-mediated rejection clinical trials across 22 countries. Studies span Phase 2, Phase 3, Not Applicable. Top locations include Los Angeles, California, United States, Seattle, Washington, United States, Durham, North Carolina, United States. Updated daily from ClinicalTrials.gov.


Antibody-mediated Rejection Trials at a Glance

7 actively recruiting trials for antibody-mediated rejection are listed on ClinicalTrialsFinder across 6 cities in 22 countries. The largest study group is Phase 2 with 2 trials, with the heaviest enrollment activity in Los Angeles, Seattle, and Durham. Lead sponsors running antibody-mediated rejection studies include Biogen, Centre Hospitalier Universitaire de Besancon, and Alexion Pharmaceuticals, Inc..

Browse antibody-mediated rejection trials by phase

Treatments under study

About Antibody-mediated Rejection Clinical Trials

Looking for clinical trials for Antibody-mediated Rejection? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Antibody-mediated Rejection trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Antibody-mediated Rejection clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting

Use of Extracorporeal Photopheresis in Kidney Transplantation: Effects on Antibody-Mediated Rejection

Antibody-mediated Rejection in Kidney Transplant
Centre Hospitalier Universitaire de Besancon31 enrolled1 locationNCT07663669
Recruiting
Phase 2

Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation

Kidney TransplantationAMRAntibody-mediated Rejection+1 more
Alexion Pharmaceuticals, Inc.45 enrolled55 locationsNCT06744647
Recruiting
Phase 2

A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)

Antibody-mediated Rejection
argenx30 enrolled23 locationsNCT06503731
Recruiting
Phase 3

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

Antibody-mediated Rejection
Biogen120 enrolled59 locationsNCT06685757
Recruiting

Biorepository and Registry for Plasma Exchange Patients

NMO Spectrum DisorderCIDPAntibody-mediated Rejection+1 more
Charles M Knudson200 enrolled1 locationNCT05004493
Recruiting
Phase 3

TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients

Antibody-mediated Rejection
Vastra Gotaland Region50 enrolled8 locationsNCT04561986
Recruiting
Not Applicable

A Prospective Randomized Trial of ECP in Subclinical AMR

Lung Transplant RejectionAntibody-mediated Rejection
Medical University of Vienna80 enrolled7 locationsNCT06112951